- Home
- CZNC vs ZURA Comparison
CZNC vs ZURA Comparison
Compare CZNC & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | ZURA |
|---|---|---|
| Founded | 1864 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.9M | 252.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CZNC | ZURA |
|---|---|---|
| Price | $21.63 | $3.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $22.00 | $11.38 |
| AVG Volume (30 Days) | 58.4K | ★ 359.5K |
| Earning Date | 01-22-2026 | 11-13-2025 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | ★ 22.09 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $109,632,000.00 | N/A |
| Revenue This Year | $5.72 | N/A |
| Revenue Next Year | $7.18 | N/A |
| P/E Ratio | $12.36 | ★ N/A |
| Revenue Growth | ★ 7.59 | N/A |
| 52 Week Low | $17.85 | $0.97 |
| 52 Week High | $22.68 | $4.68 |
Technical Indicators
Market Signals| Indicator | CZNC | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 75.33 | 58.62 |
| Support Level | $19.93 | $3.58 |
| Resistance Level | $20.67 | $3.94 |
| Average True Range (ATR) | 0.42 | 0.24 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 96.51 | 95.69 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.